🎉 Health Canada Provides a No Objection Letter for ATMA’s N500 Phase II Clinical Trial Application

A means to incorporating Psychedelic Therapy

CALGARY, AB, Sept. 23, 2021 /CNW/ – ATMA Journey Centers Inc. (“ATMA”), an Alberta-based company focused on delivering innovative psychedelic-assisted therapies internationally, unveils the development of its Therapist Network Services Program (TNSP) aimed at providing a B2B turnkey solution for mental health care professionals to incorporate Psychedelic-assisted Psychotherapy into their practices.  

The current shortage of mental health professionals in Canada is creating a substantial mental health accessibility gap. The ongoing waves of Covid-19 variants are only exacerbating the mental health crisis. Psychedelic-assisted Therapy can be a catalyst in alleviating this rising burden on the mental health care system and patient accessibility. For therapists, the current process of adding Psychedelic-assisted Therapy to their practice is often not feasible without committing significant time and resources. Building infrastructure services around therapists and providing necessary tools is one way to encourage higher engagement of mental health care professionals in Psychedelic Medicine. Vu Tran, ATMA Co-CEO, stated,

“We see a 20% rate of participation of Canadian therapists as being the critical mass to providing sufficient accessibility and possibly bringing a balance back to the mental health care system.”

ATMA is committed to creating an inclusive service model for therapists to add psychedelic-assisted therapies to their current practice through a one-stop technology platform that connects the whole psychedelic service ecosystem with therapists. Introducing ATMA’s Therapist Network Services Program (TNSP), providing:

  • Education and Training (the foundation of TNSP);
  • An online community network of like-minded Therapists;
  • Curated resources and regular expert Speakers;
  • A tool kit of how to integrate Psychedelic-assisted Therapy into practice;
  • Clinical Trial participation;
  • Medicine Sourcing and Prescribing Physician Services;
  • Ancillary services to support Psychedelic Therapy in your Practice;
  • A Therapist/Client Interface acts as a psychedelic therapy directory to serve Patients and Clients, helping them access participating Therapists locally.

The foundation of the TNSP is our Education Curriculum.  ATMA began a Psychedelic-assisted Therapy Training Program in the spring of 2021 and has experienced significant interest and uptake of the training. Every training course offered has sold out. Our current goal is to train 800 therapists through 2022. Vu Tran commented,

“Early-stage demand from Therapists suggests this is easily achievable. However, we hope to scale that much higher to meet the Canadian Therapists’ 20% participation rate.”

Building foundation and infrastructure takes time,

“for those who think it is still too early, we say there is little time to waste to educate adequately, train and build support services around enough mental health care professionals to provide these alleviating therapies to Canadians in need of them.”

The knowledge of effectively providing Psychedelic Therapy exists here and now. ATMA is doing the work of gathering, curating, and packaging it in an integral, scalable, and user-friendly way for Therapists to integrate it into their Practice. We aim to build a broad bridge from Traditional Psychotherapy to Psychedelic-assisted Psychotherapy” to create greater accessibility for all Canadians.

“Psychedelic treatments are here, but doctors aren’t prepared.”

LA TIMES Op-Ed Aug 29, 2021 Rick Doblin & Jennifer Ouyang Altman

In partnership with Wayfound Mental Health Group, ATMA aims to address the issue Rick Doblin conveyed in the August 2021 op-ed.

“It is a tall order, but we are preparing for the hard work ahead, and we are open to working with any parties in the industry that shares the vision of greater accessibility of these effective therapies.”   -Vu Tran, ATMA Co-CEO.

Wayfound Mental Health CEO Dr. Megan McElheran expressed:

“We are committed to supporting mental health professionals to access a high standard of clinical training in Psychedelic-assisted Psychotherapy, as we understand how crucial mental health professionals will be to the continued development of the Psychedelics Industry. We want to stay ahead of the tide and engage as many mental health professionals as possible in training opportunities with Psychedelic Medicine and Psychedelic-assisted Psychotherapy so that the Mental Health Industry is ready when legalization occurs.”

ATMA is a Canadian company focused on delivering practical and innovative healing and transformative experiences that leverage the potential of Psychedelic Medicine to awaken the inner healer and allow a deeper connection with self, with others, and with the beauty of our world. ATMA was the first private company in Canada to conduct legal Psychedelic-assisted Therapy with Psilocybin under a Section 56 Exemption granted by Health Canada and continues to work to provide Psilocybin-assisted Therapy care to Health Canada approved palliative care patients for compassionate reasons.

Wayfound Mental Health Group Inc., and its predecessor companies, have been proudly serving the community in Calgary since 1999. Wayfound has grown to become a national mental health service provider and, in addition to work in psychedelic training, is focused on innovation in mental health program development and delivery. The mental health professionals at Wayfound bring years of experience working with clients across the lifespan and suffering from various mental health conditions. Wayfound focuses on service provision for first responders and public safety personnel who have suffered operational stress injuries in the line of duty. The organization believes that access to mental health care should be a right, not a privilege, and they advocate for the importance of mental health care being as commonplace as physical health care.

For further information:

MEDIA CONTACT: David Harder, Co-CEO, ATMA Journey Centers Inc., david@atmajourney.com

More News and Media:

Health Canada Provides a No Objection Letter for ATMA’s N500 Phase II Clinical Trial Application, Paving the Way for the Largest Psilocybin Trial to Date

ATMA’s N500 Phase II Clinical Trial will assess psilocybin efficacy in frontline healthcare professionals suffering from COVID-19-related mental wellness challenges. CALGARY, AB, Sept. 14, 2022 /CNW/ – ATMA Journey Centers Inc. (“ATMA”), an Alberta-based company focused on the international delivery of innovative psychedelic-assisted therapy solutions, announced today that it has received approval from Health Canada to move forward with its

Psychedelic Breakthrough

Breakthroughs in the Therapy Room – Hope for Treatment Resistant Mental Illness?

By Rachel Dundas, Registered Psychologist Certified Trauma Practitioner What does it mean to be an effective therapist? Surely, most new graduates are entering the therapy profession with energy, enthusiasm, and aspirations to support and empower their clientele. Intentions, however, do not always translate to therapeutic effectiveness. Does being an effective therapist mean you have a

ATMA Journey Centers observes positive outcomes from a Phase I clinical trial of psilocybin in healthy participants

Fourteen healthy subjects completed an experiential session after receiving 25 mg psilocybin  – Results of this phase I study will inform the design of Phase II study in frontline healthcare workers, examining the efficacy of psilocybin for Covid-related stress. Calgary, September 7, 2022 — ATMA Journey Centers (the “Company”), a company providing therapist training and support, has

Thank You Letter

Dear mental healthcare professionals, A deep heart-felt thank you is warranted to you for bearing the weight of the current mental health crisis, especially during these last tough couple of years. I have heard from many of your peers regarding the increased pressure, overburdening workloads, and feelings of burnout that have become an all too frequent occurrence.

Breaking Through the Stigma

By David Harder, ATMA co-founder and co-CEO I met with a gentleman – a pastor of sorts – from my former religious life. We sat down to enjoy a pint and a burger at a local watering hole. It had been many years since we had last spoken, simply due to the chaos of life,

How To Change Your Mind

Upon the release of his book How to Change Your Mind, Michael Pollan sparked a major shift in the mindset of numerous therapists and medical professionals, as well as the general public. At the time of its publication in the spring of 2019, discussions surrounding psychedelics were happening, but in small, hushed groups of underground

Clinical Trials and Psychedelics

Clinical trials are the standard way to evaluate the safety and efficacy of new drugs (including psychedelic drugs) for medical use. Clinical trials also serve to test novel treatment options, explore ways to improve quality of life for people living with illnesses or diseases, and assess whether a new drug or treatment has fewer side

Psilocybin-assisted Therapy: The Safe and Effective Alternative

Psilocybin-assisted therapy is becoming an increasingly widespread treatment for various mental health conditions. However, many healthcare professionals may be hesitant to use this type of treatment with their patients because of the misconception that psychedelics are dangerous and unsafe. This blog post will share evidence of the safety of psilocybin as an effective treatment option

Scroll to Top